About Venter Pharma
Venter Pharma is a company based in Alcobendas (Spain) founded in 2003. Venter Pharma operates in a competitive market with competitors including Prometheus Laboratories, Viome Life Sciences, NinePoint Medical, InDex Pharmaceuticals and Given Imaging, among others.
- Headquarter Alcobendas, Spain
- SectorsHealthcare
- Email••••••••
- Website venterpharma.com
- Social LinkedIn
- Latest Funding Round$56.04K (USD), Grant
Feb 2015
- InvestorsEuropean Union
& 2 more
Funding Insights of Venter Pharma
- Total Rounds 3
- Last Round Grant — $56,042
- Investors Count 3
All 3 funding rounds of Venter Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2015 | $56,042 | Grant | – | – | |
| Oct 2014 | $63,090 | Grant | – | – | |
| Mar 2014 | – | Series A | – | Ferrer | – |
3 investors in total: 3 institutional.
Investors in Venter Pharma
Venter Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Ferrer and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Prescription drugs are manufactured by Ferrer in Barcelona since 1959. | 1959 | ferrer.com | Barcelona, Spain |
Investor details for Venter Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Venter Pharma
1 people are tracked at Venter Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Manuel Castellón Leal | CEO | Leadership |
Complete people profiles for Venter Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Venter Pharma
3 dated milestones of Venter Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Venter Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $56K.
Competitors of Venter Pharma
Venter Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prometheus Laboratories, Viome Life Sciences, NinePoint Medical, InDex Pharmaceuticals and Given Imaging, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| prometheuslabs.com | 1995 | San Diego, United States | – | 474 | Diagnostics and therapeutics for gastrointestinal and personalized medicine are developed. | |
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| ninepointmedical.com | 2008 | Bedford, United States | $98.26M | 25 | Optical coherence tomography systems for tissue microstructure imaging are developed. | |
| indexpharma.com | 2000 | Stockholm, Sweden | $45.42M | – | DNA-based immunomodulatory drugs for ulcerative colitis are developed. | |
| givenimaging.com | 1998 | Minneapolis, United States | – | – | Capsule endoscopy systems for GI imaging | |
| enterasense.com | 2016 | Galway, Ireland | $1.14M | – | Ingestible biosensor for GI disease | |
| gtechmedical.com | 2010 | Mountain View, United States | $6.93M | 3 | Diagnostic device company | |
| xillix.com | 2002 | Toronto, Canada | $5.5M | – | Develops real-time fluorescence imaging systems for medical applications. | |
| goodgut.eu | 2014 | Girona, Spain | $900,240 | – | Diagnosis and treatment of digestive diseases based on intestinal microbiota analysis | |
| stelladx.com | 2020 | New York, United States | – | – | Molecular diagnostics solutions for esophageal diseases are developed. |
Detailed competitors of Venter Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Venter Pharma
The website of Venter Pharma (venterpharma.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 29.2% vs previous month
Similar companies to Venter Pharma
10 companies that operate in the same segment as Venter Pharma (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Venter Pharma
Venter Pharma was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Venter Pharma is headquartered in Alcobendas, Spain. It is registered at Alcobendas, Comunidad De Madrid, Spain.
Venter Pharma was founded in 2003 in Alcobendas, Spain, within the pharmaceutical sector focused on digestive disorders. Emphasis is placed on high-prevalence conditions like lactose intolerance and inflammatory illnesses. LacTEST, a noninvasive oral diagnostic using Gaxilose, was developed alongside a xylose enzymatic assay for hypolactasia detection. Adaptation of LacTEST for children is in progress, with Horizon 2020 funding secured for Phase I lactase development as a gastrointestinal disease biomarker.
Venter Pharma's top competitors include Viome Life Sciences, Prometheus Laboratories and NinePoint Medical.
Venter Pharma has 3 investors. Key investors include European Union, Ferrer, and EIC Fund.